Explorez tous les épisodes du podcast Pharma Digest

• Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play
• Ambrosia scores $100M series B to take next-gen oral GLP-1 into the clinic
• Merck enlists antibody hunter Infinimmune for $838M biobucks pact

• Mapping the Trillion-Gene Universe: The Startup That Wants to Teach AI the Language of Life
• Why Data Infrastructure Determines AI Success in Drug Discovery
• PhenoTips, Health Institutions Launch C$5.4M AI Genomic Medicine Initiative in Canada

AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flops

Lilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75B

Merck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivals

• The Value of Prediction, and Cost of Success, in Drug Hunting
• Merck hands over $20M in IBD drug target deal with Flagship's Quotient
• The N-of-1 Revolution in Personalized Medicine

- Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition

- OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline

- Sarepta's big bet on Arrowhead's siRNA assets yields early data

• Baylor College of Medicine Taps Nautilus’ Voyager for Cancer Proteomics
• The Download: OpenAI is building a fully automated researcher, and a psychedelic trial blind spot
• From scientist to bioinformatician: how AI coding tools dissolved the activation energy barrier
  

• Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial
• STAT+: A biotech turns to Apple Watch to study its Parkinson’s drug
• Which FDA Division Has the Most Stability As AI Tools Get Adopted Across the Agency?

• With its first AI mod­el re­lease, Xaira tests scal­ing laws in vir­tu­al cells
• NVIDIA GTC 2026: Agentic AI Inflection Hits Healthcare and Life Sciences
• DOE Announces $293M Funding Opportunity as Genesis Mission Moves Toward Operational Phase

• Pfizer's hotly tipped breast cancer prospect delivers phase 2 win
• Aspen's 1-year data for Parkinson's cell therapy plant seeds for phase 3 trial
• Crossbow hits $77M series B round to bankroll quiver of T-Bolts

• Roche inks Nvidia deal to bolster AI factory, speed drug and diagnostic development
• Why most labs are not ready for AI: Cenevo shares what must change
• French AI Startup Building World Models Raises $1.03 billion

• Structure touts 16% weight loss for aleniglipron as 'highest efficacy' for an oral GLP-1 yet
• R1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatment
• Danish biotech Gubra plots Roivant-like model to churn out new companies

• Stop asking for an AI strategy: 3 questions clinical leaders should ask instead
• The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption
• Real-World Evidence Meets Machine Learning: What It Takes to Future-Proof Evidence Generation
  

• CytomX surges on positive data for ‘masked’ ADC in colorectal cancer
• Astellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 years
• JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity — NeuroSense Therapeutics

Startup Waiv Spins Out of Owkin With $33M to Bring AI Precision to Cancer Decisions

Artificial Intelligence and the Data Quality Problem No One Can Ignore

Microsoft Enters Healthcare Chatbot Race with Copilot Health

• GSK’s RSV vaccine wins broader FDA clearance
• Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial
• With FDA go ahead, a China biotech notches a first in cell therapy testing

• An AI Driven Approach to Address the Non-Responder Gap in Radiopharmaceutical Therapy
• Agentic AI Swarms Degrade Decision-Making
• STAT+: AI agents are rapidly spreading in health care, but validation is lacking

• Ultragenyx gene therapy hits co-primary endpoint in phase 3 rare disease study, teeing up potential win
• BridgeBio's muscle weakness data impress ahead of FDA filing
• Fledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program

• STAT+: New nonprofit launches with at least $500 million to modernize scientific process for AI era
• Bota/Enhe’s SAION AI push toward closed‑loop, machine‑protocol‑driven biomanufacturing
• Tailored Training Can Address Biopharma Skills Shortage

• Regeneron's obesity drug shows Zepbound-like efficacy in phase 3
• Tenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater China
• $270M RNA Drug Spinout Targets Rare Genetic Cardiomyopathies

• Smarter Filings, Smarter Factories
• Health AI startup to benefit from $1 billion funding round for Yann LeCun’s AMI
• Breakout Ventures launches $114M AI-focused fund

• Vertex races to FDA after phase 3 kidney disease data impress analysts
• Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma
• FDA reconsidering Capricor’s snubbed DMD cell therapy after 'lifting' rejection
  

• CVS, Humana & More Are Turning to Google’s AI Models
• AI Startups Are Tying Fees to Completed Tasks. Will Hospitals Buy In?
• For Anthropic, Pragmatism Is the More Trustworthy Position

• FDA issues speedy approval to J&J’s Tecvayli-Darzalex combo
• Xenon phase 3 epilepsy readout 'blows away' expectations, stock soars
• BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3

• Future of Health Tech: From Structured Data to Scalable AI
• Capturing the Vibe at ViVE 2026, Healthcare Executives Share Insights on Medication Adherence and Implementing AI
• Privacy Expectations in Consumer AI Tools: How Patient Use of ChatGPT Health and Claude Differs From HIPAA-Regulated Care

• Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal
• FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap
• Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'

• Opinion: AI could revolutionize antibiotics — but the market is standing in the way
• Third Way Health Secures $15M to Streamline Front-Office Operations for Medical Practices
• In­vestors are pump­ing mon­ey in­to AI tools for health in­sur­ers

• UCB enters TCE space with $1.1B deal for Chinese biotech's autoimmune candidate
• New cancer cases prompt Kyowa to discontinue late‑stage autoimmune disease program
• FDA details rationale for rejecting rare disease gene therapy from Regenxbio
  

• STAT+: FDA grants breakthrough status to generative AI chatbot
• AI Startups ROI Reckoning: What 4 VCs Say Matters Now
• Actionable AI in Clinical Settings: Trust and Transparency as the Core Operating System

[AI Generated Biotech and Pharma News]

• Ascendis wins FDA approval of dwarfism drug
• Lynk points to phase 3 eczema win as more proof of next-gen JAK inhibitor's potential
• Novo Nordisk teams with Langer-founded biotech for oral obesity drugs

• Senhwa's CX-4945 targets CK2 kinase with dual tumor and immune modulatory mechanisms; CellType's AI platform aims to expand indications and improve clinical success via multi-omics analysis and translational validation.
• Generate's $400M IPO signals strong investor confidence, driven by AI-designed pipelines including GB-0895, an AI-optimized TSLP inhibitor with potential to disrupt asthma treatment.
• hysiology remains foundational for translating AI and sensor data into clinically relevant therapies, aiding in anticipating off-target effects and enhancing regulatory acceptance.

• BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
  
• UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy
  
• Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
  

[AI Generated AI in Pharma News]

• Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle
• Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs
• XtalPi's AI + Robotics Platform Powers First Clinical Milestone for ReviR's Rare Neurological Drug RTX-117

[AI Generated Pharma and Biotech News]

• United Therapeutics' phase 3 win tees up filing to challenge J&J in cardiac condition
• FDA fully releases clinical hold on Intellia CRISPR gene therapy
• Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs

[AI Generated AI in Pharma and Biotech News]

• QScreen AI secured CAD 500,000 in financing to expand its AI and quantum-driven health screening solutions across North America and Mexico.

• Investment is surging in the health insurance sector, highlighted by Handl Health’s $14.2 million Series A funding for AI tools that streamline underwriting and claims management.

• Roche and Insilico Medicine (in collaboration with Pfizer) are leading a shift toward AI-driven drug discovery, using deep learning and generative AI to identify therapeutic candidates and optimize protein engineering.

[AI Generated Pharma News]

• Earendil Labs and WuXi XDC have partnered to integrate machine learning with the WuXiTecan-2 platform to optimize the design and targeting precision of antibody-drug conjugates (ADCs).

• ImmVira is expanding clinical trials for MVR-T3011, a genetically engineered oncolytic virus, to treat BCG-naïve bladder cancer patients as a dual-action alternative to traditional therapies.
• Protagonist Therapeutics exited its profit-sharing deal with Takeda for the drug rusfertide, accepting a $400 million one-time payment to independently fund its broader pipeline, including the asset ICOTYDE™.

[AI Generated Pharma News]

• Pfizer has acquired the Chinese commercialization rights for Sciwind’s GLP-1 drug, ecnoglutide, in a deal valued at up to $495 million to target the region's growing metabolic disorder market.

• GSK is expanding its respiratory and cardiovascular pipeline through a $950 million acquisition of 35Pharma, gaining access to a promising activin signaling inhibitor for pulmonary hypertension.

• Novo Nordisk has entered a potential $2.1 billion partnership with Vivtex to leverage proprietary technology for developing oral formulations of biologic drugs like GLP-1 therapies.

[AI Generated AI in Drug Discovery News]

• Dimension has secured $500 million to fund approximately 24 companies, aiming to integrate computational power with life sciences to accelerate drug discovery.
• The BiopharmaTrend 2026 watchlist identifies startups founded in 2021 that are using AI platforms to move away from single-asset strategies toward more precise, platform-based drug development.
• Y Combinator is backing the Yale spinout Patientdesk.ai, which utilizes "Agentic AI" to eliminate inefficiencies and improve data-driven forecasting within clinical trials.

[AI Generated AI in Drug Discovery News]

• Turbine is utilizing a recently secured $25 million in Series B funding to advance its "lab-in-the-loop" AI platform that simulates biological processes to reduce the cost and risk of drug discovery.

• Evinova has established strategic partnerships with AstraZeneca, Astellas, and Bristol Myers Squibb to integrate AI across the drug development spectrum, focusing on clinical trial data analysis and early-stage candidate selection.

• Owkin has launched K Pro, an AI co-pilot that uses federated learning and biological reasoning to analyze fragmented biomedical data, aiming to significantly accelerate drug discovery timelines and enhance precision medicine.

[AI generated Pharma News]

• Turbine's Virtual Lab: The Hungary-based firm raised $25 million to scale its AI platform that simulates cellular biology to accelerate drug discovery.
• Global Licensing Surges: Highlighting Chinese expansion, Frontier signed a $1 billion kidney disease deal with GSK, while Harbour BioMed penned a $1.2 billion cancer treatment agreement with Solstice.
• Astellas & Vir Partnership: A $1.7 billion collaboration focuses on VIR-5500, a prostate cancer therapy that demonstrated a 45% response rate in early trials.